CYBX up +2.42% percent right now. $CYBX High is at 51.33 and the Low 49.90 with current volume of 115,006.
Recent News posted below.
CYBX Cyberonics Inc Recent Headline News
Cyberonics Shares Down 12.7% Since SmarTrend's Sell Call (CYBX)
Comtex SmarTrend(R) - Mon Nov 10, 9:58AM CST
SmarTrend identified a Downtrend for Cyberonics (NASDAQ:CYBX) on August 22nd, 2014 at $57.31. In approximately 3 months, Cyberonics has returned 12.71% as of today's recent price of $50.02.
CYBX: 51.02 (+1.02)
Seats remaining for the Houston area MVP and Cyberonics Veteran and Transitioning Military Re-careering Event
PR Newswire - Mon Nov 10, 7:00AM CST
On November 19th, 2014, Houston, TX based Cyberonics (www.cyberonics.com) will partner with the MedTech and BioTech Veterans Program (www.mvpvets.org) to conduct a re-careering event for transitioning military and veterans in the Houston, Texas area. There are still seats remaining for this free and innovative opportunity for veterans and transitioning military personnel to learn more about employment opportunities at Cyberonics and in the Medical Device Manufacturing industry.
CYBX: 51.02 (+1.02)
Cyberonics To Report Fiscal Year 2015 Second Quarter Results And Host Webcast And Conference Call On November 20, 2014
PR Newswire - Thu Nov 06, 8:00AM CST
Cyberonics, Inc. (NASDAQ:CYBX) today announced that the company will report financial results for the second quarter ended October 24, 2014 on Thursday, November 20, 2014 before regular market trading hours. The company will conduct a conference call to discuss those results on the same day at 8:00 AM Central Time (9:00 AM Eastern Time).
CYBX: 51.02 (+1.02)
10.4% Return Seen to Date on SmarTrend Cyberonics Call (CYBX)
Comtex SmarTrend(R) - Mon Oct 27, 11:10AM CDT
SmarTrend identified a Downtrend for Cyberonics (NASDAQ:CYBX) on August 22nd, 2014 at $57.31. In approximately 2 months, Cyberonics has returned 10.44% as of today's recent price of $51.32.
CYBX: 51.02 (+1.02)
MedTech and BioTech Veterans Program and Cyberonics Announce Veteran and Transitioning Military Re-careering Event
PR Newswire - Tue Oct 14, 7:00AM CDT
On November 19, 2014, Houston, TX-based Cyberonics, Inc. (NASDAQ: CYBX; www.cyberonics.com) will partner with the MedTech and BioTech Veterans Program (www.mvpvets.org) to conduct a re-careering event for transitioning military and veterans in south Texas.
CYBX: 51.02 (+1.02)
Downtrend Call Working As Cyberonics Stock Falls 12.4% (CYBX)
Comtex SmarTrend(R) - Thu Oct 02, 10:05AM CDT
SmarTrend identified a Downtrend for Cyberonics (NASDAQ:CYBX) on August 22nd, 2014 at $57.31. In approximately 1 month, Cyberonics has returned 12.38% as of today's recent price of $50.21.
CYBX: 51.02 (+1.02)
Interesting CYBX Put And Call Options For November 22nd
DividendChannel.com - Tue Sep 30, 10:03AM CDT
Investors in Cyberonics, Inc. saw new options begin trading this week, for the November 22nd expiration.
CYBX: 51.02 (+1.02)
Insider Trading Alert - CYBX, RSG And RRC Traded By Insiders
at The Street - Fri Sep 26, 9:04AM CDT
Stocks with insider trader activity include CYBX, RSG and RRC
RSG: 39.45 (-0.08), RRC: 73.47 (+1.09), CYBX: 51.02 (+1.02)
Shares of CYBX Down 10.9% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Thu Sep 25, 9:29AM CDT
SmarTrend identified a Downtrend for Cyberonics (NASDAQ:CYBX) on August 22nd, 2014 at $57.31. In approximately 1 month, Cyberonics has returned 10.92% as of today's recent price of $51.05.
CYBX: 51.02 (+1.02)
Cyberonics Sluggish on Poor Q2, Faces Reimbursement Issues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 24, 4:05PM CDT
On Sep 24, we issued an updated research report on Cyberonics Inc. (CYBX).
INGN: 25.24 (+0.59), EW: 124.37 (-0.23), HOLX: 26.51 (-0.04), CYBX: 51.02 (+1.02)
Insider Trading Alert - AMTD, CYBX And RSG Traded By Insiders
at The Street - Mon Sep 15, 10:00AM CDT
Stocks with insider trader activity include AMTD, CYBX and RSG
RSG: 39.45 (-0.08), AMTD: 35.32 (+0.26), CYBX: 51.02 (+1.02)
The Market for Neurotechnology: 2014-2018 - Technology, Markets, Competitors and Growth Rates in Four Key Segments
M2 - Fri Sep 12, 5:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lwdj78/the_market_for) has announced the addition of the "The Market for Neurotechnology: 2014-2018" report to their offering. This newly published market research report is the most comprehensive and up-to-date publication available covering the neurotechnology industry. The report takes an in-depth look at the technology, markets, competitors, and growth rates in four key segments of the neurotechnology industry in the years 2014 through 2018. It forecasts the number of systems to be sold, worldwide revenue, compound annual growth rates, and competitor market shares for several key product categories making up the neural prostheses, neuromodulation, neurorehabilitation, and neurosensing segments of the industry. The Market for Neurotechnology: 2014-2018 covers in detail all the key public companies and the most significant emerging and more established non-public firms in the industry. The report also features in-depth profiles of major research institutions in the U.S. and abroad involved with neurotechnology developments, and traces the commercial activity that is emerging from each. The report not only looks at future financial projections, it covers likely technology trends and product developments that will impact the neurotechnology industry in the years ahead, such as: - Nanowire brain implants guided into position through the cerebral vasculature. - Optical stimulation devices that solve many of the problems associated with electrical charge buildup. - Microfluidic interfaces that combine electrical stimulation and drug delivery. The Market for Neurotechnology: 2014-2018 examines each of the neurological diseases and disorders that represent a significant market potential for neurotechnology products, including established markets like Parkinson's disease, chronic pain, and urinary incontinence, as well as emerging markets such as tinnitus, vestibular disorders, obesity, migraine, sleep disorders, and affective disorders. And it is the only report on the neurotechnology industry to forecast new product categories in neurorehabilitation and neurosensing such as brain analysis systems and neurorobotic systems. Key Topics Covered: 1. Introduction 2. Industry Background 3. Neurotechnology Markets 4. Product Categories 5. Company Profiles 6. Market Activity 7. Research Institutions 8. Funding Sources 9. Future Directions 10. Company Listings Companies Mentioned - Advanced Bionics - Boston Scientific - CVRx - Cochlear Ltd. - Cyberonics - Medtronic - Natus Medical - Nevro Corp. - Several Others - Spinal Modulation - St. Jude Medical For more information visit http://www.researchandmarkets.com/research/lw...market_for
BSX: 13.34 (-0.11), BABY: 34.04 (-0.44), MDT: 68.76 (+0.05), STJ: 65.49 (-0.21), CYBX: 51.02 (+1.02)
Post Earnings Update: Cyberonics Has Sunk 5.1% Lower in Past 2 Weeks (CYBX)
Comtex SmarTrend(R) - Mon Sep 08, 6:59AM CDT
18 days ago, on August 21st, 2014, Cyberonics (NASDAQ:CYBX) reported its earnings. Analysts, on average, expected earnings of $0.56 per share on sales of $73.9 million. The company actually reported EPS of $0.53 on sales of $72.0 million, missing EPS estimates by $0.03 and missing revenue estimates by $1.9 million. Shares of Cyberonics have slipped from $58.27 to $55.30, representing a loss of 5.1%, since the company reported earnings 18 days ago.
CYBX: 51.02 (+1.02)
Cyberonics Down 3.6% despite Favorable ANTHEM-HF Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 2:30PM CDT
Based on the encouraging ANTHEM-HF study results, Cyberonics (CYBX) is now eagerly awaiting the commercial launch of its new VITARIA System for ART.
ATEC: 1.43 (+0.01), RTIX: 4.99 (-0.12), ERB: 2.87 (+0.13), CYBX: 51.02 (+1.02)
ANTHEM-HF Shows Autonomic Regulation Therapy Is Safe And Improves Heart Function In Patients With Chronic Heart Failure
PR Newswire - Tue Sep 02, 8:00AM CDT
Cyberonics, Inc. (NASDAQ: CYBX), today announced results from the ANTHEM-HF clinical study. Results of the study presented by a prominent heart failure specialist during a major European cardiology congress and concurrently published by the Journal of Cardiac Failure show Autonomic Regulation Therapy (ART) in patients with moderate to severe chronic heart failure and impaired heart function is safe, improves the heart's ability to pump blood, and reduces symptoms associated with chronic heart failure. More than six million people in Europe have chronic heart failure, a syndrome characterized by the heart's inability to pump sufficient blood to meet the metabolic demands of the body.
CYBX: 51.02 (+1.02)
MedTech Defies Sequestration, M&As Steal the Show - Industry Outlook
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 3:31AM CDT
MedTech Defies Sequestration, M&As Steal the Show - Industry Outlook
ABMD: 33.00 (+0.01), BDX: 128.42 (+0.12), MDT: 68.76 (+0.05), ARAY: 7.05 (+0.15), NUVA: 43.06 (+0.59), CYBX: 51.02 (+1.02), BSX: 13.34 (-0.11), JNJ: 108.92 (+0.10), ICUI: 81.89 (+10.08), WMGI: 28.07 (+0.10), OPK: 8.50 (-0.13), RMD: 50.96 (-0.06), ABBV: 63.67 (-0.12), SYK: 88.48 (+0.04), ZMH: 110.92 (+0.50), ABT: 44.27 (+0.18), SMA: 9.27 (-0.07), BCR: 163.49 (-0.38), MCK: 201.94 (+0.66), TMO: 117.78 (+0.93), PFE: 30.26 (+0.06), COV: 93.41 (-0.23), EW: 124.37 (-0.23), MYL: 53.44 (-0.51), COO: 160.02 (-0.40), CG: 29.17 (+0.11), ABAX: 53.27 (+0.33), BAX: 70.75 (+0.12), DGX: 63.17 (+0.48), STJ: 65.49 (-0.21), THOR: 27.67 (+0.37), HGR: 20.71 (+0.12)
MedTech Defies Sequestration, M&As Steal the Show - Investment Ideas
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 3:31AM CDT
MedTech Defies Sequestration, M&As Steal the Show - Investment Ideas
ABMD: 33.00 (+0.01), BDX: 128.42 (+0.12), MDT: 68.76 (+0.05), ARAY: 7.05 (+0.15), NUVA: 43.06 (+0.59), CYBX: 51.02 (+1.02), BSX: 13.34 (-0.11), JNJ: 108.92 (+0.10), ICUI: 81.89 (+10.08), WMGI: 28.07 (+0.10), OPK: 8.50 (-0.13), RMD: 50.96 (-0.06), ABBV: 63.67 (-0.12), SYK: 88.48 (+0.04), ZMH: 110.92 (+0.50), ABT: 44.27 (+0.18), SMA: 9.27 (-0.07), BCR: 163.49 (-0.38), MCK: 201.94 (+0.66), TMO: 117.78 (+0.93), PFE: 30.26 (+0.06), COV: 93.41 (-0.23), EW: 124.37 (-0.23), MYL: 53.44 (-0.51), COO: 160.02 (-0.40), CG: 29.17 (+0.11), ABAX: 53.27 (+0.33), BAX: 70.75 (+0.12), DGX: 63.17 (+0.48), STJ: 65.49 (-0.21), THOR: 27.67 (+0.37), HGR: 20.71 (+0.12)
Recent News posted below.
CYBX Cyberonics Inc Recent Headline News
Cyberonics Shares Down 12.7% Since SmarTrend's Sell Call (CYBX)
Comtex SmarTrend(R) - Mon Nov 10, 9:58AM CST
SmarTrend identified a Downtrend for Cyberonics (NASDAQ:CYBX) on August 22nd, 2014 at $57.31. In approximately 3 months, Cyberonics has returned 12.71% as of today's recent price of $50.02.
CYBX: 51.02 (+1.02)
Seats remaining for the Houston area MVP and Cyberonics Veteran and Transitioning Military Re-careering Event
PR Newswire - Mon Nov 10, 7:00AM CST
On November 19th, 2014, Houston, TX based Cyberonics (www.cyberonics.com) will partner with the MedTech and BioTech Veterans Program (www.mvpvets.org) to conduct a re-careering event for transitioning military and veterans in the Houston, Texas area. There are still seats remaining for this free and innovative opportunity for veterans and transitioning military personnel to learn more about employment opportunities at Cyberonics and in the Medical Device Manufacturing industry.
CYBX: 51.02 (+1.02)
Cyberonics To Report Fiscal Year 2015 Second Quarter Results And Host Webcast And Conference Call On November 20, 2014
PR Newswire - Thu Nov 06, 8:00AM CST
Cyberonics, Inc. (NASDAQ:CYBX) today announced that the company will report financial results for the second quarter ended October 24, 2014 on Thursday, November 20, 2014 before regular market trading hours. The company will conduct a conference call to discuss those results on the same day at 8:00 AM Central Time (9:00 AM Eastern Time).
CYBX: 51.02 (+1.02)
10.4% Return Seen to Date on SmarTrend Cyberonics Call (CYBX)
Comtex SmarTrend(R) - Mon Oct 27, 11:10AM CDT
SmarTrend identified a Downtrend for Cyberonics (NASDAQ:CYBX) on August 22nd, 2014 at $57.31. In approximately 2 months, Cyberonics has returned 10.44% as of today's recent price of $51.32.
CYBX: 51.02 (+1.02)
MedTech and BioTech Veterans Program and Cyberonics Announce Veteran and Transitioning Military Re-careering Event
PR Newswire - Tue Oct 14, 7:00AM CDT
On November 19, 2014, Houston, TX-based Cyberonics, Inc. (NASDAQ: CYBX; www.cyberonics.com) will partner with the MedTech and BioTech Veterans Program (www.mvpvets.org) to conduct a re-careering event for transitioning military and veterans in south Texas.
CYBX: 51.02 (+1.02)
Downtrend Call Working As Cyberonics Stock Falls 12.4% (CYBX)
Comtex SmarTrend(R) - Thu Oct 02, 10:05AM CDT
SmarTrend identified a Downtrend for Cyberonics (NASDAQ:CYBX) on August 22nd, 2014 at $57.31. In approximately 1 month, Cyberonics has returned 12.38% as of today's recent price of $50.21.
CYBX: 51.02 (+1.02)
Interesting CYBX Put And Call Options For November 22nd
DividendChannel.com - Tue Sep 30, 10:03AM CDT
Investors in Cyberonics, Inc. saw new options begin trading this week, for the November 22nd expiration.
CYBX: 51.02 (+1.02)
Insider Trading Alert - CYBX, RSG And RRC Traded By Insiders
at The Street - Fri Sep 26, 9:04AM CDT
Stocks with insider trader activity include CYBX, RSG and RRC
RSG: 39.45 (-0.08), RRC: 73.47 (+1.09), CYBX: 51.02 (+1.02)
Shares of CYBX Down 10.9% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Thu Sep 25, 9:29AM CDT
SmarTrend identified a Downtrend for Cyberonics (NASDAQ:CYBX) on August 22nd, 2014 at $57.31. In approximately 1 month, Cyberonics has returned 10.92% as of today's recent price of $51.05.
CYBX: 51.02 (+1.02)
Cyberonics Sluggish on Poor Q2, Faces Reimbursement Issues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 24, 4:05PM CDT
On Sep 24, we issued an updated research report on Cyberonics Inc. (CYBX).
INGN: 25.24 (+0.59), EW: 124.37 (-0.23), HOLX: 26.51 (-0.04), CYBX: 51.02 (+1.02)
Insider Trading Alert - AMTD, CYBX And RSG Traded By Insiders
at The Street - Mon Sep 15, 10:00AM CDT
Stocks with insider trader activity include AMTD, CYBX and RSG
RSG: 39.45 (-0.08), AMTD: 35.32 (+0.26), CYBX: 51.02 (+1.02)
The Market for Neurotechnology: 2014-2018 - Technology, Markets, Competitors and Growth Rates in Four Key Segments
M2 - Fri Sep 12, 5:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lwdj78/the_market_for) has announced the addition of the "The Market for Neurotechnology: 2014-2018" report to their offering. This newly published market research report is the most comprehensive and up-to-date publication available covering the neurotechnology industry. The report takes an in-depth look at the technology, markets, competitors, and growth rates in four key segments of the neurotechnology industry in the years 2014 through 2018. It forecasts the number of systems to be sold, worldwide revenue, compound annual growth rates, and competitor market shares for several key product categories making up the neural prostheses, neuromodulation, neurorehabilitation, and neurosensing segments of the industry. The Market for Neurotechnology: 2014-2018 covers in detail all the key public companies and the most significant emerging and more established non-public firms in the industry. The report also features in-depth profiles of major research institutions in the U.S. and abroad involved with neurotechnology developments, and traces the commercial activity that is emerging from each. The report not only looks at future financial projections, it covers likely technology trends and product developments that will impact the neurotechnology industry in the years ahead, such as: - Nanowire brain implants guided into position through the cerebral vasculature. - Optical stimulation devices that solve many of the problems associated with electrical charge buildup. - Microfluidic interfaces that combine electrical stimulation and drug delivery. The Market for Neurotechnology: 2014-2018 examines each of the neurological diseases and disorders that represent a significant market potential for neurotechnology products, including established markets like Parkinson's disease, chronic pain, and urinary incontinence, as well as emerging markets such as tinnitus, vestibular disorders, obesity, migraine, sleep disorders, and affective disorders. And it is the only report on the neurotechnology industry to forecast new product categories in neurorehabilitation and neurosensing such as brain analysis systems and neurorobotic systems. Key Topics Covered: 1. Introduction 2. Industry Background 3. Neurotechnology Markets 4. Product Categories 5. Company Profiles 6. Market Activity 7. Research Institutions 8. Funding Sources 9. Future Directions 10. Company Listings Companies Mentioned - Advanced Bionics - Boston Scientific - CVRx - Cochlear Ltd. - Cyberonics - Medtronic - Natus Medical - Nevro Corp. - Several Others - Spinal Modulation - St. Jude Medical For more information visit http://www.researchandmarkets.com/research/lw...market_for
BSX: 13.34 (-0.11), BABY: 34.04 (-0.44), MDT: 68.76 (+0.05), STJ: 65.49 (-0.21), CYBX: 51.02 (+1.02)
Post Earnings Update: Cyberonics Has Sunk 5.1% Lower in Past 2 Weeks (CYBX)
Comtex SmarTrend(R) - Mon Sep 08, 6:59AM CDT
18 days ago, on August 21st, 2014, Cyberonics (NASDAQ:CYBX) reported its earnings. Analysts, on average, expected earnings of $0.56 per share on sales of $73.9 million. The company actually reported EPS of $0.53 on sales of $72.0 million, missing EPS estimates by $0.03 and missing revenue estimates by $1.9 million. Shares of Cyberonics have slipped from $58.27 to $55.30, representing a loss of 5.1%, since the company reported earnings 18 days ago.
CYBX: 51.02 (+1.02)
Cyberonics Down 3.6% despite Favorable ANTHEM-HF Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 2:30PM CDT
Based on the encouraging ANTHEM-HF study results, Cyberonics (CYBX) is now eagerly awaiting the commercial launch of its new VITARIA System for ART.
ATEC: 1.43 (+0.01), RTIX: 4.99 (-0.12), ERB: 2.87 (+0.13), CYBX: 51.02 (+1.02)
ANTHEM-HF Shows Autonomic Regulation Therapy Is Safe And Improves Heart Function In Patients With Chronic Heart Failure
PR Newswire - Tue Sep 02, 8:00AM CDT
Cyberonics, Inc. (NASDAQ: CYBX), today announced results from the ANTHEM-HF clinical study. Results of the study presented by a prominent heart failure specialist during a major European cardiology congress and concurrently published by the Journal of Cardiac Failure show Autonomic Regulation Therapy (ART) in patients with moderate to severe chronic heart failure and impaired heart function is safe, improves the heart's ability to pump blood, and reduces symptoms associated with chronic heart failure. More than six million people in Europe have chronic heart failure, a syndrome characterized by the heart's inability to pump sufficient blood to meet the metabolic demands of the body.
CYBX: 51.02 (+1.02)
MedTech Defies Sequestration, M&As Steal the Show - Industry Outlook
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 3:31AM CDT
MedTech Defies Sequestration, M&As Steal the Show - Industry Outlook
ABMD: 33.00 (+0.01), BDX: 128.42 (+0.12), MDT: 68.76 (+0.05), ARAY: 7.05 (+0.15), NUVA: 43.06 (+0.59), CYBX: 51.02 (+1.02), BSX: 13.34 (-0.11), JNJ: 108.92 (+0.10), ICUI: 81.89 (+10.08), WMGI: 28.07 (+0.10), OPK: 8.50 (-0.13), RMD: 50.96 (-0.06), ABBV: 63.67 (-0.12), SYK: 88.48 (+0.04), ZMH: 110.92 (+0.50), ABT: 44.27 (+0.18), SMA: 9.27 (-0.07), BCR: 163.49 (-0.38), MCK: 201.94 (+0.66), TMO: 117.78 (+0.93), PFE: 30.26 (+0.06), COV: 93.41 (-0.23), EW: 124.37 (-0.23), MYL: 53.44 (-0.51), COO: 160.02 (-0.40), CG: 29.17 (+0.11), ABAX: 53.27 (+0.33), BAX: 70.75 (+0.12), DGX: 63.17 (+0.48), STJ: 65.49 (-0.21), THOR: 27.67 (+0.37), HGR: 20.71 (+0.12)
MedTech Defies Sequestration, M&As Steal the Show - Investment Ideas
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 3:31AM CDT
MedTech Defies Sequestration, M&As Steal the Show - Investment Ideas
ABMD: 33.00 (+0.01), BDX: 128.42 (+0.12), MDT: 68.76 (+0.05), ARAY: 7.05 (+0.15), NUVA: 43.06 (+0.59), CYBX: 51.02 (+1.02), BSX: 13.34 (-0.11), JNJ: 108.92 (+0.10), ICUI: 81.89 (+10.08), WMGI: 28.07 (+0.10), OPK: 8.50 (-0.13), RMD: 50.96 (-0.06), ABBV: 63.67 (-0.12), SYK: 88.48 (+0.04), ZMH: 110.92 (+0.50), ABT: 44.27 (+0.18), SMA: 9.27 (-0.07), BCR: 163.49 (-0.38), MCK: 201.94 (+0.66), TMO: 117.78 (+0.93), PFE: 30.26 (+0.06), COV: 93.41 (-0.23), EW: 124.37 (-0.23), MYL: 53.44 (-0.51), COO: 160.02 (-0.40), CG: 29.17 (+0.11), ABAX: 53.27 (+0.33), BAX: 70.75 (+0.12), DGX: 63.17 (+0.48), STJ: 65.49 (-0.21), THOR: 27.67 (+0.37), HGR: 20.71 (+0.12)
